Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure
Because heart failure (HF) is more lethal than some of the common malignancies in the general population, such as prostate cancer in men and breast cancer in women, there is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, especially concerning congestion, the most...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-12-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2021.22 |
| _version_ | 1826933270818848768 |
|---|---|
| author | Marko Kumric Tina Ticinovic Kurir Josko Bozic Duska Glavas Tina Saric Bjørnar Marcelius Domenico D’Amario Josip A Borovac |
| author_facet | Marko Kumric Tina Ticinovic Kurir Josko Bozic Duska Glavas Tina Saric Bjørnar Marcelius Domenico D’Amario Josip A Borovac |
| author_sort | Marko Kumric |
| collection | DOAJ |
| description | Because heart failure (HF) is more lethal than some of the common malignancies in the general population, such as prostate cancer in men and breast cancer in women, there is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, especially concerning congestion, the most common reason for the hospitalisation of patients with worsening of HF. Furthermore, despite diuretics being the mainstay of treatment for volume overload in HF patients, no randomised trials have shown the mortality benefits of diuretics in HF patients, and appropriate diuretic titration strategies in this population are unclear. Recently, carbohydrate antigen (CA) 125, a well-established marker of ovarian cancer, emerged as both a prognostic indicator and a guide in tailoring decongestion therapy for patients with HF. Hence, in this review the authors present the molecular background regarding the role of CA125 in HF and address valuable clinical aspects regarding the relationship of CA125 with both prognosis and therapeutic management in HF. |
| first_indexed | 2024-03-07T17:41:15Z |
| format | Article |
| id | doaj.art-ad5dac50b9f145f38d1048a50f6fd133 |
| institution | Directory Open Access Journal |
| issn | 2057-7540 2057-7559 |
| language | English |
| last_indexed | 2025-02-17T17:28:25Z |
| publishDate | 2021-12-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Cardiac Failure Review |
| spelling | doaj.art-ad5dac50b9f145f38d1048a50f6fd1332024-12-14T16:03:11ZengRadcliffe Medical MediaCardiac Failure Review2057-75402057-75592021-12-01710.15420/cfr.2021.22Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart FailureMarko Kumric0Tina Ticinovic Kurir1Josko Bozic2Duska Glavas3Tina Saric4Bjørnar Marcelius5Domenico D’Amario6Josip A Borovac7Department of Pathophysiology, University of Split School of Medicine, Split, CroatiaDepartment of Pathophysiology, University of Split School of Medicine, Split, Croatia; Department of Endocrinology and Diabetology, University Hospital of Split, Split, CroatiaDepartment of Pathophysiology, University of Split School of Medicine, Split, CroatiaClinic for Heart and Vascular Diseases, University Hospital of Split, Split, CroatiaInstitute of Emergency Medicine of Split-Dalmatia County, Split, CroatiaDepartment of Pathophysiology, University of Split School of Medicine, Split, CroatiaDepartment of Cardiovascular and Thoracic Sciences, Fondazione Policlinico A Gemelli IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, ItalyDepartment of Pathophysiology, University of Split School of Medicine, Split, Croatia; Clinic for Heart and Vascular Diseases, University Hospital of Split, Split, Croatia; Department of Health Studies, University of Split, Split, CroatiaBecause heart failure (HF) is more lethal than some of the common malignancies in the general population, such as prostate cancer in men and breast cancer in women, there is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, especially concerning congestion, the most common reason for the hospitalisation of patients with worsening of HF. Furthermore, despite diuretics being the mainstay of treatment for volume overload in HF patients, no randomised trials have shown the mortality benefits of diuretics in HF patients, and appropriate diuretic titration strategies in this population are unclear. Recently, carbohydrate antigen (CA) 125, a well-established marker of ovarian cancer, emerged as both a prognostic indicator and a guide in tailoring decongestion therapy for patients with HF. Hence, in this review the authors present the molecular background regarding the role of CA125 in HF and address valuable clinical aspects regarding the relationship of CA125 with both prognosis and therapeutic management in HF.https://www.cfrjournal.com/articleindex/cfr.2021.22 |
| spellingShingle | Marko Kumric Tina Ticinovic Kurir Josko Bozic Duska Glavas Tina Saric Bjørnar Marcelius Domenico D’Amario Josip A Borovac Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure Cardiac Failure Review |
| title | Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure |
| title_full | Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure |
| title_fullStr | Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure |
| title_full_unstemmed | Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure |
| title_short | Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure |
| title_sort | carbohydrate antigen 125 a biomarker at the crossroads of congestion and inflammation in heart failure |
| url | https://www.cfrjournal.com/articleindex/cfr.2021.22 |
| work_keys_str_mv | AT markokumric carbohydrateantigen125abiomarkeratthecrossroadsofcongestionandinflammationinheartfailure AT tinaticinovickurir carbohydrateantigen125abiomarkeratthecrossroadsofcongestionandinflammationinheartfailure AT joskobozic carbohydrateantigen125abiomarkeratthecrossroadsofcongestionandinflammationinheartfailure AT duskaglavas carbohydrateantigen125abiomarkeratthecrossroadsofcongestionandinflammationinheartfailure AT tinasaric carbohydrateantigen125abiomarkeratthecrossroadsofcongestionandinflammationinheartfailure AT bjørnarmarcelius carbohydrateantigen125abiomarkeratthecrossroadsofcongestionandinflammationinheartfailure AT domenicodamario carbohydrateantigen125abiomarkeratthecrossroadsofcongestionandinflammationinheartfailure AT josipaborovac carbohydrateantigen125abiomarkeratthecrossroadsofcongestionandinflammationinheartfailure |